Vazyme(SH:688105) 智通财经网·2025-09-24 09:46Core Viewpoint - The company, Novogene (688105.SH), has announced that its wholly-owned subsidiary, Nanjing Novogene Medical Technology Co., Ltd., has obtained multiple medical device registration certificates for its series of diagnostic reagents for the nervous system in China [1] Group 1: Product Development and Innovation - The company is leveraging its proprietary antibody technology platform to continuously enrich its Alzheimer's disease blood test product series based on global authoritative guidelines [1] - The company is focusing on the central nervous system's major diseases by innovatively developing precise detection and diagnostic products for conditions such as Parkinson's disease and brain injuries [1] Group 2: Market Position and Strategy - The newly obtained product registration certificates signify that the company's related products have received market access qualifications in China [1] - The company aims to address unmet clinical needs in the field of neurological diseases, enhancing the product strength and influence of its chemiluminescence platform [1] - The company is committed to improving the diagnosis and treatment services for brain health and cognitive disorders in alignment with the "Healthy China Strategy" [1]